Illinois Municipal Retirement Fund decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 28.5% in the third quarter, Holdings Channel.com reports. The firm owned 32,862 shares of the biotechnology company’s stock after selling 13,103 shares during the period. Illinois Municipal Retirement Fund’s holdings in BioMarin Pharmaceutical were worth $1,972,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Parkside Financial Bank & Trust lifted its holdings in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 187 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $39,000. Keating Financial Advisory Services Inc. purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth approximately $56,000. Root Financial Partners LLC bought a new position in BioMarin Pharmaceutical during the 3rd quarter valued at approximately $88,000. Finally, Parallel Advisors LLC increased its position in BioMarin Pharmaceutical by 33.9% during the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 448 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.
BioMarin Pharmaceutical Stock Performance
Shares of NASDAQ BMRN opened at $57.23 on Monday. The firm’s 50-day moving average price is $58.86 and its 200-day moving average price is $58.48. The company has a quick ratio of 1.32, a current ratio of 2.44 and a debt-to-equity ratio of 0.56. The company has a market cap of $11.09 billion, a PE ratio of -572.30, a PEG ratio of 0.77 and a beta of 0.21. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the company earned $0.12 earnings per share. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.20 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on BMRN. Oppenheimer lowered their price objective on BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating for the company in a research note on Tuesday, November 3rd. Wall Street Zen raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Sunday, November 8th. Canaccord Genuity Group raised their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a report on Monday, August 10th. Royal Bank Of Canada lowered their price target on BioMarin Pharmaceutical from $62.00 to $60.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 3rd. Finally, Stifel Nicolaus lowered their price target on BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Tuesday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.22.
Read Our Latest Stock Report on BMRN
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
Further Reading
- Five stocks we like better than BioMarin Pharmaceutical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
